Reusable Respimat for Spiriva and Spiolto

Advertorial
By
Boehringer Ingelheim
-

ADVERTORIAL BY BOEHRINGER INGELHEIM

Australia’s only soft mist inhaler, Respimat, is now available as a reusable device and is included on the PBS for asthma or COPD patients using Spiriva Respimat (tiotropium) or Spiolto Respimat (tiotropium/olodaterol).1-3

The new-generation Respimat inhaler has enhanced features and can be used with up to six cartridges, rather than being disposed of and replaced each time the medication runs out.4-5

Each year, 1.7 million fewer inhalers could be prevented from entering Australian landfill as existing Spiriva and Spiolto Respimat patients transition to the reusable inhaler.6

Discuss the transition to, and use of, the Respimat reusable inhaler with patients.

Instructional videos are available at: www.respimat.com.au (HCP password: softmist)

References

  1. Department of Health. PBS Schedule. 1 March 2021.
  2. Spiriva Respimat Approved Production Information. June 2020
  3. Spiolto Respimat Approved Production Information. November 2020
  4. Spiriva Respimat Instruction For Use.
  5. Spiolto Respimat Instruction For Use.
  6. Data on File. Boehringer Ingelheim.

Please review Product Information before prescribing. Full Product Information is available at www.boehringer-ingelheim.com.au/PI . Further Information is available from Boehringer Ingelheim Pty Ltd.

INDICATIONS: SPIRIVA RESPIMAT: Long term maintenance treatment of bronchospasm and dyspnoea associated with chronic obstructive pulmonary disease (COPD). Prevention of COPD exacerbations. SPIOLTO RESPIMAT: Once-daily maintenance bronchodilator treatment to relieve symptoms in adult patients with COPD. CONTRAINDICATIONS: SPIRIVA RESPIMAT and SPIOLTO RESPIMAT: Hypersensitivity   to tiotropium bromide, olodaterol (Spiolto only), atropine or its derivatives, or to any of the excipients. PRECAUTIONS: SPIRIVA  RESPIMAT  and  SPIOLTO  RESPIMAT: Should  not  be  used: more frequently than once daily;  for  relief  of  acute  symptoms,  treatment of acute  episodes  of bronchospasm,  immediate hypersensitivity  reactions,  paradoxical  bronchospasm,  narrow-angle glaucoma, prostatic hyperplasia, bladder neck obstruction, urinary retention, micturition difficulties, recent myocardial infarction (<6 months for SPIRIVA, <12 months for SPIOLTO), unstable or life-threatening cardiac arrhythmia within past year, hospitalisation for heart failure within past year, moderate to severe renal impairment(CrCL ≤50 mL/min), pregnancy, lactation and children. Avoid solution or mist entering eyes. SPIRIVA RESPIMAT: Should not be used for: first-line treatment for asthma, dry mouth. SPIOLTO  RESPIMAT: Should  not  be  used: in treatment  of asthma (LABAs may  increase   the   risk   of   asthma-related hospitalisations and death); initiated in acutely deteriorating COPD, severe hepatic impairment, convulsive disorders, thyrotoxicosis, QT interval prolongation, unusual responsiveness to sympathomimetic amines; increases in pulse rate, blood pressure and/or  symptoms of clinically  significant  cardiovascular  effect, paroxysmaltachycardia (>100 beats per minute), hypokalaemia, hyperglycaemia. INTERACTIONS: SPIRIVA RESPIMAT and SPIOLTO RESPIMAT: Co-administration with anticholinergic drugs. SPIOLTO RESPIMAT: Co-administration with adrenergic agents, xanthine derivatives, steroids, non-potassium paring diuretics, beta-blockers, MAO inhibitors, tricyclic antidepressants, QTc interval prolonging drugs, LAMAs, LABAs. ADVERSE EFFECTS: SPIRIVA RESPIMAT: Common: Dry mouth, usually mild. SPIOLTO RESPIMAT: Very common: nasopharyngitis. Common: pneumonia, bronchitis, influenza, urinary tract infection, sinusitis, cough, dyspnoea, back pain, overdose, headache. Others, see full PI. DOSAGE: SPIRIVA RESPIMAT: For oral inhalation. 5μg tiotropium given as two puffs once daily, at the same time each day. SPIOLTO RESPIMAT: For oral inhalation. 5μg tiotropium and 5 μg olodaterol given as two puffs once daily, at the same time each day. Do not exceed recommended dose. Cartridges to be used only with RESPIMAT inhaler. March 2020

RESPIMAT®, SPIRIVA® and SPIOLTO® are registered trademarks of Boehringer Ingelheim. Boehringer Ingelheim Pty Ltd. ABN 52 000 452 308. 78 Waterloo Road, North Ryde, NSW 2113. PC-AU-101906. February 2021.